Study identifier:NIS-NHU-SER-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Seroquel XR in schizophrenia relapse prevention
schizophrenia relapse prevention
-
No
-
All
1600
Observational
18 Years - 70 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2010 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improve the relapse prevention in schizophrenic outpatients
Location
Location
Baja, Hungary
Location
Barcs, Hungary
Location
Budapest, Hungary
Location
Cegled, Hungary
Location
Debrecen, Hungary
Location
Dombovar, Hungary
Location
Dunaujvaros, Hungary
Location
Eger, Hungary
Arms | Assigned Interventions |
---|---|
1 Schizophrenic outpatients | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.